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In the present article, we discuss the various ambiguous aspects of the immune sys-
tem that render this complex biological network so highly ﬂexible and able to defend the
host from different external invaders. This ambiguity stems mainly from the property of
the immune system to be both protective and harmful. Immunity cannot be fully pro-
tective without producing a certain degree of damage (immunopathology) to the host.
The balance between protection and tissue damage is, therefore, critical for the estab-
lishment of immune homeostasis and protection. In this review, we will consider as
ambiguous, various immunological tactics including: (a) the opposing functions driving
immune responses, immune-regulation, and contra-regulation, as well as (b) the phenome-
non of chronic immune activation as a result of a continuous cross-presentation of apoptotic
T cells by dendritic cells. All these plans participate principally to maintain a state of chronic
low-level inﬂammation during persisting infections, and ultimately to favor the species
survival.
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INTRODUCTION
To better understand the mechanisms underlying the immune
response, immunologists have attempted to establish some general
rules of how pathogens are fought and possibly defeated. One of
the predominant views has considered the immune response as a
network where different types of specialized immune cells interact
with each other to ensure host survival. This “cooperative” inter-
pretation has been recently challenged by the observation that the
immune system is committed not only to attacking “invaders,” but
also to suppressing the ongoing immune response, most likely to
limit excessive immunopathology. The concept that the immune
response might act to maintain a homeostatic balance between
aggression and suppression has, therefore, emerged. It has been
also hypothesized that the inhibitory activity of the immune sys-
tem is the predominant one. For example, the immune system
allows bacteria of the intestinal ﬂora to survive and to produce
substances (e.g., vitamin B12) that are essential for the well-being
of the host (Barthlott et al., 2003; Coombes et al., 2005). However,
even this hypothesis does not appear to be completely satisfy-
ing. The possible emergence of self-reactive immune responses,
of useless or even harmful antibodies, of chronic inﬂammatory
infectious diseases represents part of the “ambiguous” aspects of
the immune system. We will, therefore, discuss how this ambigu-
ity has paradoxically evolved to favor host survival, and how the
immune system represents a valid biological model to highlight
the evolutionistic value of the ambiguity itself.
The etymology of the term ambiguity is derived from Latin
ambagere, which means the ability “to push something in differ-
ent directions” or “to be understood in different ways.” Semantics
identiﬁes ambiguity with the polysemy (from the Greek word:
polysemos), which is the property of a word to express more
than one meaning (Jakobson, 1995). In artwork, ambiguity is
a critical element of esthetical information. Aristotle, the Greek
philosopher, celebrated that nohumanwork canbedeﬁned as“art”
in the absence of a certain degree of ambiguity (Hintikka, 1959).
In philosophy, ambiguity has been recently considered as “a pro-
ductive element that is both against and beyond any metaphysical
dogma, passing through the crisis of subjectivity” or, alternatively,
“the action by which any event is made possible, by either direct
creationor construction frompre-existing elements”(Pasqualotto,
1997). Thus, ambiguity can represent a prerequisite of the creativ-
ity that has, psychologically speaking,“the ability to produce ideas
or elements providing novel and/or alternative solutions to a wide
array of problems.” From a biological point of view, all these def-
initions seem to be quite theoretical or even intangible. However,
ambiguity and the resulting creativity could be concretely related
to the capacity of a biological system to put into action different
mechanisms simultaneously that are only apparently opposite but
ultimately result in an evolutionary advantage for the host1. To
better understand how ambiguity can be applied to the immune
response, a short review of the fundamental aspects of immunity
should be conducted.
AMBIGUITY AND B OR T CELL ONTOGENESIS
The adaptive immune response is mediated by the B and T cells,
both recognizing antigens through highly specialized and clonally
distributed B cell or T cell receptors (BCRs andTCRs). To allow the
generation of a huge number of antigen speciﬁcity, the immune
1Here, we will not consider the deﬁnition of ambiguity generally attributed by the
psychoanalysis, as the incapacity to discriminate between ego and non-ego poten-
tially leading to severe social and psychic disorders Bleger (1967). Simbiosis y
ambiguedad, estudio psiconalitico. Editorial Paidos, Buenos Aires. If ever, accord-
ing to the etymologic, semantic, or philosophic deﬁnitions reported above, we will
consider the biological ambiguities (such as those cellular and molecular largely
described for the immunology in this review) as critical events participating to the
general homeostasis of the individual that ultimately favors the species survival.
www.frontiersin.org February 2012 | Volume 3 | Article 18 | 1
Barnaba et al. Ambiguity in immunology
system has evolved a very effective molecular organization of gene
expression for the production of BCRs and TCRs following the
encounter with self antigens, which occurs at the level of central
lymphoid tissues (the bone marrow for B cells and the thymus for
T cells). In particular, the recombination mechanisms (including
gene rearrangement, junctional diversity, and N-region addition)
enable a limited number of variable (V ), diversity (D), and joining
(J) minigene elements to produce about 1013–1018 different genes
encoding for an equal multiplicity of antigen receptors (Tone-
gawa, 1983; Yoshikai et al., 1984; Pullen et al., 1989; Oettinger
et al., 1990; Shinkai et al., 1992; Wayne et al., 1994; Agrawal et al.,
1998; West et al., 2005; Murphy et al., 2007). This enormous BCR
or TCR diversity confers the potential immune identity to each
individual, because the lymphocyte repertoire – and, hence, the
capacity to respond to antigens – is customized for each individ-
ual, being different even amongst monozygotic twins. However,
such an extraordinarily elegant mechanism, the aim of which is to
protect the host fromanypossible invader, also produces undesired
effects. The main side effect of such a broad response is the genera-
tion of “unwanted”B or T lymphocytes (“ﬁrst level of ambiguity”).
Indeed,amultitude of developing lymphocyteswill result (a) igno-
rant because they will never meet their speciﬁc antigens through-
out the life of a single individual; (b) apparently useless such as
those able to recognize selective pathogen-associated epitopes, but
not critical for the pathogen neutralization; and (c) dangerous,
such as those autoreactive. To limit the generation and/or the
harmful activity of these cells, the host has evolved different check-
points to render the immune response mostly effective in ﬁghting
dangerous microorganisms without damaging host tissues. With
regard to the T cell development, the ﬁrst checkpoint determines
that only a tiny population of thymocytes likely recognizing ubiq-
uitous self antigens that are presented by cortical thymic epithelial
cells (cTECs) can survive (positive selection mechanism; Snod-
grass et al., 1985; Marrack et al., 1989; Jameson and Bevan, 1998;
McCaughtry et al., 2008). This mechanism allows the deletion of
a huge number of useless or harmful T cells that otherwise would
ﬂood and destroy the “vital space” at the level of central or periph-
eral lymphoid tissues, or may potentially induce autoimmunity
(McCaughtry et al., 2008). As a consequence, only the thymocytes
that have been positively selected through the recognition of ubiq-
uitous self-epitopes could progress and reach the thymus medulla,
where they will be submitted to a second checkpoint (medullar
negative selection). A fundamental role is played by the autoim-
mune regulator (AIRE) gene,which allows the expression of awide
array of peripheral tissue-speciﬁc proteins in medullary (m)TECs
(Anderson et al., 2002; Liston et al., 2003; Kuroda et al., 2005;
Zhu et al., 2006; Gillard et al., 2007). Thymocytes with high afﬁn-
ity/avidity to tissue-speciﬁc self-proteins presented by both mTEC
or thymic dendritic cells (DCs; which have phagocytosed mTEC)
are deleted, a process which protects the host from the generation
of autoreactive T cells with a high potential to induce organ-
speciﬁc autoimmunity (Killeen et al., 1998). Similarly, self-reactive
B lymphocytes are deleted in the bone marrow (Neuberger, 1997;
Pillai, 1999; Hardy and Hayakawa, 2001). Nevertheless, a number
of autoreactive T or B cells with high afﬁnity antigen receptors
have a second chance to survive because of a mechanism known
as receptor editing (Tiegs et al., 1993; McGargill et al., 2000). As
a consequence, all mature B or T lymphocytes migrating into the
periphery on the one hand can recognize self-epitopes with low
afﬁnity, but they can be potentially protective by recognition of
microbial antigens with high afﬁnity, on the other hand. This
process is extremely advantageous for the economy of the immune
system because it allows: (a) dangerous lymphocytes recognizing
self-proteins with high afﬁnity/avidity are deleted, thus minimiz-
ing the emergence of autoimmunity; (b) a restrict lymphocyte
repertoire as compared with what is potentially generated upon
somatic recombination harbors the peripheral lymphoid tissues
to defend the host from possible harmful aliens; (c) this repertoire
of mature T or B lymphocytes is however enough to recognize an
almost limitless number of microbial determinants and to con-
trol the continuous emergence of mutations of immunodominant
epitopes.
In some T cells, the ambiguity of antigen recognition may be
further ampliﬁed by a dual TCR expression. Indeed, the inefﬁ-
ciency of allelic exclusion following the rearrangement of TCR
alpha chains (Casanova et al., 1991;Borgulya et al., 1992) allows the
generation of a signiﬁcant proportion of mature T cells harboring
two functional TCRs with distinct antigen speciﬁcities (Padovan
et al., 1993). Controversy still exists about the signiﬁcance of dual
TCR expression in the responses to foreign (He et al., 2002; Dash
et al., 2010) or self antigens (Elliott and Altmann, 1995), in the
development of regulatory T (Treg) cells (Tuovinen et al., 2006)
or in microbial triggers of autoimmunity (Ji et al., 2010). Anyway,
the availability of a second speciﬁcity by a stimulated T cell may be
interpreted as a“reserve”of response,whichmay extend immunity
to additional exogenous as well to endogenous antigens.
Therefore, the intrinsic ambiguity of this process [i.e., mat-
uration of protective lymphocytes is dependent on (low afﬁn-
ity) self-antigen recognition] provides the host with a signiﬁ-
cant advantage, which outweighs the side effects (autoimmunity,
chronic inﬂammatory diseases. . .) that are generally controlled by
the mechanisms of peripheral tolerance.
Evolution may have selected those processes of T cell develop-
ment aimed at maximizing repertoire width, even at the expenses
of the single individual safeguard. A proof of this possibility comes
from the hypothesis that vertebrates developed the thymus from
gut-associated lymphoid tissue (GALT; Matsunaga and Rahman,
2001). Indeed,due to structural constraints, inGALTonly negative
but not positive selection of T cells can efﬁciently take place (Mat-
sunaga andRahman,2001). This scenariomay suggest interpreting
ambiguity in antigen recognition as an advantageous feature that
has been ﬁxed by natural selection.
THE AMBIGUITY OF THE PERIPHERAL IMMUNE RESPONSE
INNATE IMMUNE CELLS AND SIGNALS
As described above, the development of the mature B- and T-cell
repertoires is dependent on recognition of self antigens in the thy-
mus and bone marrow, respectively: mature B and T cells can then
ﬁght invaders as a result of their capacity to cross-react with single
pathogen-associated epitopes. This high level of ambiguity of the
immune system has led to the hypothesis that the main function
of the immune response is to discriminate the dangerous/infectious
from the non-dangerous/non-infectious rather than the foreign
from the non-foreign (Matzinger, 1994; Gallucci and Matzinger,
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2001; Janeway and Medzhitov, 2002; Medzhitov and Janeway,
2002). According to these theories, innate immunity plays a key
role through the presence of sensors, such as the toll-like receptors
(TLRs) expressed mainly by innate immune cells (e.g.,monocytes,
neutrophils, DCs. . .) and B lymphocytes, or intracellular nuclear
oligomerization domain (NOD)-like receptors (Matzinger, 2002;
Inohara et al., 2005; Akira et al., 2006; Fritz et al., 2006; Mey-
lan et al., 2006; Petrilli et al., 2007). These receptors can identify
dangerous/infectious signals because they recognize molecular
patterns common to different pathogens [pathogen-associated
molecular patterns (PAMPs), such as lipopolysaccharide (LPS),
bacterial DNA, or viral RNA], or dangerous compounds, such
as endogenous (e.g., uric acid causing the gout. . .) or exogenous
(e.g., asbestos causing mesothelioma or asbestosis, silica dust caus-
ing silicosis. . .) crystals (Meylan et al., 2006; Otsuki et al., 2007;
Petrilli et al., 2007; Pope and Tschopp, 2007). As regards B cells,
PAMPs deliver via TLRs critical costimulatory signals required
for the plasma cell differentiation and the generation of mem-
ory B cells (Lanzavecchia and Sallusto, 2007). Once activated via
TLRs, innate immune cells do the following: (a) induce an ade-
quate inﬂammatory response in order to respond very early to
pathogens and to limit the microbial invasion and (b) generate an
effective adaptive immune response through cooperation (Zarem-
ber and Godowski, 2002; Viglianti et al., 2003; Hoebe et al., 2004;
Schulz et al., 2005; Kawai and Akira, 2006; Matzinger, 2007). In
addition, the tissues undergoing inﬂammation critically interact
with innate immune cells to inﬂuence the type of local adap-
tive immune responses (Cho, 2008; Coombes and Powrie, 2008).
Matzinger and Kamala (2011) have proposed that tissue-derived,
rather than pathogen-derived, signals mostly dictate which classes
of effector cells and molecules will be induced to achieve the max-
imal protection with the minimal damage in a given organ. On
the one hand, this complex network has evolved to determine a
high defense/offense ratio at the level of the different types of
inﬂamed tissues; on the other hand, it can produce tissue dam-
age and develop immunopathology under certain conditions. The
critical issue is if and how this ambiguous aspect of the immune
system is biologically advantageous and/or necessary.
B CELL RESPONSES
As discussed above, the enormous BCR repertoire, which has
evolved to recognize as many different pathogens as possible, has
two main – and apparently contradictory – effects. The prin-
cipal protective effect results in the production of neutralizing
antibodies addressed to ﬁght pathogens, and to control the con-
tinuous emergence of microbial mutants (Figure 1). In contrast,
the “side effect” is the emergence of potentially harmful antibod-
ies (i.e., the autoreactive), or of those apparently useless, such as
the wide range of antimicrobial antibodies that are generated in
response to a given pathogen, but do not appear to be critical
FIGURE 1 | Protective and harmful B cell responses leading to infection
resolution. Upon infection by a given pathogen (i.e., a virus), innate immunity
is ﬁrstly elicited (1) and acts both to promptly control the pathogen spread and
to cooperate with the virus-related antigens (presented by professional APCs)
for the priming of the adaptive immunity harm (2). Both pathogen-speciﬁc
antibodies (particularly, the non-neutralizing, which represent the majority of
antibodies generated in response to a given pathogen!) and autoantibodies
(that can be generated via cross-reactivity or bystander mechanisms) can form
immune complexes (ICs) and produce damage through the cooperation with
the innate immune system (macrophages, complement factors, inﬂammatory
cytokines. . .) (3). However, neutralizing, non-neutralizing virus-speciﬁc B cells,
as well as the autoreactive, act in concert to ﬁght the pathogen: the
neutralizing in an antigen-speciﬁc manner, the non-neutralizing and
autoreactive in a bystander manner via the activation of the phagocytic system
by ICs resulting in the ampliﬁcation of the inﬂammatory responses (acute
disease).This inﬂammatory storm is self-limited, when the pathogen is cleared.
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for pathogen clearance (non-neutralizing or non-protective anti-
bodies; Figure 1). In particular, autoreactive antibodies can be
elicited through the cross-reactivity between self and non-self
antigens (Rose and Mackay, 2000; Benoist and Mathis, 2001),
or generated in response to cryptic self-epitopes that have been
unveiled from injured cells, during the course of a given infection
or an inﬂammatory process (Salemi et al., 1995; Barnaba, 1996;
Di Rosa and Barnaba, 1998; Rice et al., 2005). Moreover, both
autoantibodies and pathogen-speciﬁc antibodies (particularly, the
non-neutralizing, which represent the majority of antibodies gen-
erated in response to a given pathogen!) can produce damage
via the formation of circulating immune complexes (ICs). The
resulting systemic inﬂammatory processes can provoke damage
in various cells (e.g., blood cells) or the formation of vasculitis
phenomena, which affect several tissues (e.g., joints, skin, kidney,
brain; Oates and Gilkeson, 2002; Rice et al., 2005; Alard et al.,
2008; Klareskog et al., 2008). However, these injuries are gener-
ally self-limited and rarely cause organ or tissue failure. Indeed,
they disappear in relation to the contraction of the protective
immune responses that have promptly cleared the pathogen. Even
under these conditions, ICs can participate to the quick ampli-
ﬁcation of the inﬂammatory cascade (via the activation of the
complement system, the innate immune cells and the huge vari-
ety of inﬂammatory molecules) that is mandatory for both the
control of the pathogen and the cooperation between the innate
immunity and the adaptive T and B cell mediated responses,
ultimately leading to recovery (Avrameas, 1991). The antibodies,
already intrinsically ambiguous per se (because of the simultane-
ous generation of both protective and dangerous antibodies that,
as previously described, is inevitable during thedevelopmentof the
lymphocyte repertoire), perform their potential functions through
equally ambiguous phenomena – protective effects strictly related
to prompt inﬂammatory reactions.
T CELL RESPONSES
Dendritic cells are essential to prime T cell responses, upon the
processing andpresentationof exogenous antigens,which are pref-
erentially presented on major histocompatibility complex (MHC)
class II molecules, or endogenous antigens, which vice-versa are
preferentially presented on MHC class I molecules. However,
the capacity of DCs to present exogenous antigens derived from
other cells (usually necrotic or apoptotic cells) or soluble anti-
gens on class I molecules is deﬁned as cross-presentation (Guer-
monprez et al., 2003; Norbury et al., 2004; Accapezzato et al.,
2005; Savina et al., 2006; Burgdorf et al., 2007; Dudziak et al.,
2007).
Distinct DC subsets spread throughout the body, and although
they share common features, they also have specialized functions.
Humans and mice display two major DC types: myeloid DCs
(myDCs, also called conventional DCs), and plasmacytoid DCs
(pDCs; Palucka et al., 2010). In humans, myDCs are subdivided
in two populations, on the basis of expression of BDCA-1 (CD1c)
or BDCA-3 (CD141). CD1c+ DCs represent the most abundant
population of myDCs, express a wider repertoire of TLRs than
the CD141+ DCs, and hence they play a key role in sensing infec-
tious/danger signals, in turn essential for their activation, migra-
tion, and T cell priming (see below). CD141+ DCs represent the
human counterpart of mouse lymphoid CD8+ DCs. Indeed, both
these subsets perform the cross-presentationmechanismwithhigh
efﬁciency, express the chemokine receptor XCR1 allowing them to
migrate in response to the speciﬁc ligand (XCR1L) that is produced
by NK and activated CD8+ T cells (Bachem et al., 2010; Crozat
et al., 2010), and express the adhesion molecule Necl2 binding to
class-I-restricted T-cell-associated molecule (CRTAM), a cell sur-
face protein primarily expressedbyNK,NK-T,and activatedCD8+
T cells. Thus, mouse CD8+ DCs and human CD141+ DCs appear
to be addressed for generation of CD8+ T cell immunity (Short-
man and Heath, 2010). BDCA-2+ pDCs express high amounts
of IL-3Rα chain (CD123) and ILT-7 and are considered the front
line in antiviral immunity owing to their capacity to rapidly pro-
duce high amounts of type I interferon in response to viruses
(Siegal et al., 1999; Cao et al., 2006). pDCs recognize viral compo-
nents and self nucleic acids through TLR7 and TLR9, and possibly
other as yet unidentiﬁed receptors (Matsui et al., 2009), allowing
the secretion of two sequential cytokines: type I IFN is respon-
sible for generation of non-Ig-secreting plasma blasts and IL-6
driving their differentiation into Ig-secreting plasma cells (Jego
et al., 2003). Recently, it has been proposed that, in addition to
their primary role to produce high levels of antiviral IFNs of type
1, pDCs are capable of performing efﬁcient antigen-presenting cell
(APC) functions (Guiducci et al., 2006; Di Pucchio et al., 2008).
Other subsets, such as DCs in B cell follicular regions or dermal
CD14+ DCs in human skin, have specialized function in their
selective districts. DCs in B cell follicular regions interact with B
cells, inducing humoral immunity to unprocessed soluble antigen
presented by these DCs (Wykes et al., 1998). Dermal CD14+ DCs
express a huge repertoire of surface C-type lectins and TLRs (van
der Aar et al., 2007; Klechevsky et al., 2009), and induce naïve T
cells to differentiate into cells with properties of T follicular helper
(TFH) cells (Klechevsky et al., 2008), able to induce naïve B cells
to produce large amounts of IgM and to induce B cells to switch
isotypes toward IgG and IgA.
All tissues are “patrolled” by conventional myDCs that, like
bifacial Janus (the most ambiguous Roman divinity), can per-
form opposing (tolerogenic or stimulatory) functions, according
to the context in which they work (Lanzavecchia and Sallusto,
2001; Steinman et al., 2003). Depending on the signal myDCs
will undergo activation/maturation, the quality of which will
determine the type of elicited adaptive immunity. Under steady
state conditions,myDCs phagocytose self antigens associated with
dying (apoptotic) tissue cells (derived from the physiological cell
turnover), process them, present the resulting peptides on MHC
class II or class I molecules and migrate into the draining lymph
nodes with very low efﬁciency, where they can induce toler-
ance or cross-tolerance of autoreactive CD4+ T cells or CD8+
T cells, respectively (peripheral tolerance; Lanzavecchia and Sal-
lusto, 2001; Steinman et al., 2003). Peripheral tolerance is enforced
by the AIRE expression in extrathymic stromally derived cells res-
ident in peripheral lymphoid organs, which hence can present a
wide array of tissue-speciﬁc antigens and are capable of interact-
ing with and deleting naïve autoreactive T cells (Gardner et al.,
2008). DCs that exist at the steady state, can also establish tol-
erance indirectly by inducing Treg cells (Roncarolo et al., 2001;
Yamazaki et al., 2006), the key cell population involved in the
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FIGURE 2 | Protective and harmfulT cell responses leading to
infection resolution. Recovery from infections is dependent on the
efﬁcient priming of T cells by professional APCs (DCs) working in concert
with other innate immune cells. The efﬁciency of DCs in migrating from
inﬂamed tissues to lymph nodes, in presenting antigens, and in T cell
priming is in turn dependent on the engagement of different types of DC
sensors by pathogens (such asTLRs engaged by PAMPs). In addition
(CD4+) Th1 cell polarization (dashed arrows) requires the presence of IFN-γ
generally donated by NK cells, and IL-12, produced by DCs. (CD4+) Th2 cell
polarization (dotted arrows) requires the presence of IL-4 particularly
produced by basophils. Whereas (CD4+) Th17 cell polarization (arrows with
dashes and dots) requires the presence of several cytokines, such as
TGF-β, IL-6, IL-1 (particularly produced by monocytes and endothelial cells),
and IL-23 (mainly produced by DCs). In all cases, the functional activity of
DCs, T, or B cells is increased by the interaction between CD40, expressed
by both DCs and B cells, and CD40 ligand (L), expressed by activatedT
cells. ThenTh1 cells display protective activity against intracellular
pathogens (i.e., viruses. . .), via both IFN-γ production (antiviral activity) and
by cooperating with B cells producing IgG1 (in humans) or IgG2 (in mice)
neutralizing antibodies. Th2 cells are protective against extracellular
pathogens, such as helminthes, via the production of a series of cytokines
(e.g., IL-4, IL-5, IL-13) addressed to provoke “allergic-like” hypersensitivity
(obtained via the recruitment of various cells, including eosinophils and
mast-cells) and production of protective IgE antibodies by B cells. Th17
cells seem to be important in ﬁghting extracellular pathogens, such as
fungal infections. (CD8+) Cytotoxic T lymphocytes (CTLs) directly kill
infected cells via the recognition of class I molecules expressing pathogen
peptides. In any case, activatedT cells can eliminate the pathogen via the
establishment of a severe inﬂammatory disease. Treg cells control
exaggerated responses or the emergence of autoreactive lymphocytes.
regulationof immune responses andhomeostasis (Sakaguchi et al.,
2010; see The Control of the Immune Response). These DCs
may not simply be unstimulated or immature. Activation of the
Wnt and β-catenin signaling pathway in DCs has been shown
to promote induced Treg cell production, at least in the mouse
(Jiang et al., 2007). Similarly, in the thymus, production of thymic
stroma lymphopoietin (TSLP) is essential for selection of naturally
occurring CD4+CD25hi Treg cells (Watanabe et al., 2005). By con-
trast, in an inﬂammatory context (mainly induced by infectious
agents or tissue-derived signals), DCs are activated (for instance,
through TLR engagement by PAMPs or necrotic cell products),
increase for a short time (West et al., 2004) the ability to inter-
nalize and to process both microbial and self antigens, as well as
they upregulate the expression of stimulatory, costimulatory, and
pro-migratorymolecules [i.e., the lymphnode-speciﬁc chemokine
receptors (Cys–Cys chemokine receptor 7, CCR7); Figure 2; Lan-
zavecchia and Sallusto, 2001; Steinman et al., 2003]. Then, they
can reach the lymph nodes, where they prime or cross-prime
both microbial- or self-antigen-speciﬁc naïve CD4+ or CD8+
T lymphocytes (Ridge et al., 1998; Schulz et al., 2005). There-
fore, the generation of autoreactive T cell responses is poten-
tially a common event occurring in relation to the protective
responses against the “invaders” (ambiguity). As a consequence,
both pathogen- and self-reactive effector T lymphocytes migrate
to the inﬂamed tissues because of the newly acquired expression
of tissue-speciﬁc chemokine receptors (Sprent and Surh, 2002;
Masopust and Ahmed, 2004; Sallusto et al., 2004; Lang et al.,
2005). According to the microenvironmental context, lympho-
cytes are polarized toward different types of effector capacities that
can provide opposing protective and harmful effects (ambiguity;
Figure 2). If DCs are conditioned by infectious or danger signals
to produce adequate amounts of IL-12, in the presence of inter-
feron (IFN)-γ, CD4+, or CD8+ T cell priming is skewed toward
the polarization of either proinﬂammatory Th1 cells or CD8+
T cells with high cytotoxic potential, respectively: these cells will
simultaneously provide protective responses against intracellular
pathogens and harmful responses via their immunopathological
activities (Romagnani, 1997). In the presence of IL-4, naïve T
www.frontiersin.org February 2012 | Volume 3 | Article 18 | 5
Barnaba et al. Ambiguity in immunology
cells preferentially differentiate into Th2 (producing IL-4, IL-5, IL-
13. . .) with protective responses against extracellular pathogens or
harmful responses in the case of allergic reactions (Nelms et al.,
1999; de Jong et al., 2005).Under conditions inwhichDCsproduce
IL-23 (another member of the IL-12 family), and in the presence
of IL-6, transforming growth factor (TGF)-β, and IL-1β, T cells
differentiate toward Th17 cells (producing IL-17), described to be
responsible for causing severe immunopathological damages (i.e.,
in several models of autoimmunity) and for providing protection
against some extra or intracellular pathogens (Acosta-Rodriguez
et al., 2007; Bettelli et al., 2007; Dong, 2008; Luger et al., 2008;
McGeachy and Cua, 2008; Curtis and Way, 2009). Sustained stim-
ulation by DCs is critical for maintaining a large pool of memory
T cells. Upon infection resolution, effector cells disappear,whereas
memory cells remain numerically constant because of the expres-
sion of receptors speciﬁc for the homeostatic (IL-7 and IL-15)
cytokines (Surh et al., 2006; Sabbagh et al., 2007). The homeo-
static proliferation of memory cells, in the absence of antigen, is
critical for prompt differentiation into effector cells should they
re-encounter the original infecting pathogen.
An additional support for the idea that DCs carry out opposing
functions according to their maturational stage and the microen-
vironment in which they work is provided by studies investigat-
ing the complex interplay amongst cross-presentation, apoptotic
cells, DCs, and stimulatory signals. The current view suggests
that, under steady state conditions, apoptotic cells are consis-
tently captured by immature DCs that in turn induce tolerance
(or cross-tolerance) of apoptotic cell-derived antigen-speciﬁc T
cells (Albert, 2004; Kazama et al., 2008). Otherwise, DCs mature
and cross-prime these T cells in the presence of sustained infec-
tious/inﬂammatory mediators, necrotic cell products, or CD4+
Th cells inducingDCmaturation via the CD40/CD40L interaction
(Inaba et al., 1998; Propato et al., 2001;Albert, 2004; Blachere et al.,
2005; Rawson et al., 2007). The rationale behind this model is that
apoptosis may be a physiological or a pathological event, depend-
ing upon the circumstances involved. Thus, apoptosis occurring
physiologically during the development of a given tissue should
cause tolerance, whereas apoptosis caused by a microbial infection
or other inﬂammatory processes should result in T cell priming
(Propato et al., 2001;Winau et al., 2006). In the steady state condi-
tions, apoptotic cells have been proposed to induce T cell deletion,
anergy, immune deviation from Th1 to Th2 responses, or Treg cell
induction (Kurts et al., 1998; Ferguson et al., 2002; Grifﬁth et al.,
2007), via a series of not completely clear mechanisms, includ-
ing the capacity of apoptotic cells to release immunosuppressive
cytokines (i.e., IL-10 or TGF-β), or to engage receptors (i.e., CD36
or phosphatidyl serine receptors) subverting the stimulatory DC
functions (Gao et al., 1998; Chen et al., 2001; Serhan and Savill,
2005). In addition, it has been demonstrated that apoptotic cell-
dependent tolerance can be determined by the caspase-induced
production of a reactive oxygen species scavenger leading to oxi-
dization and inactivation of the high mobility group protein B1, a
powerful danger signal normally involved in the full DC activation
and immune response initiation (Kazama et al., 2008). How-
ever, the presence of sustained infectious/inﬂammatory media-
tors, necrotic cell products or CD4+ T cell help can bypass the
tolerogenic effects of apoptotic cells and induce DCs to prime or
cross-prime T cells (Inaba et al., 1998; Propato et al., 2001; Albert,
2004; Blachere et al., 2005; Rawson et al., 2007; Tesniere et al.,
2008).
Our previous data proposed that an alternative mechanism of
abrogation of the apoptosis-associated tolerance can take place
via the expression of CD40L by apoptotic cells (Figure 3; Propato
et al., 2001). CD40L+ apoptotic cells can be derived from acti-
vated CD40L+ T cells that undergo apoptosis once they have
performed their effector function in a given inﬂamed tissue or
upon infection with proapoptotic viruses, such as HIV. CD40L+
apoptotic T cells directly induce DC maturation and condition
them to induce cross-priming of CD8+ T cells speciﬁc to apoptotic
cell-associated self antigens, irrespective of additional exogenous
signals (Figure 3). In contrast, if apoptotic T cells are CD40L−
(such as those derived from resting T cells), the help of a third
party activated T cell or surrogate CD40L molecule is needed for
priming (Figure 3). The ﬁnding that CD40L+ apoptotic T cells
induce DC maturation and cross-priming without the addition
of exogenous stimuli indicates that the surface phenotype and
possibly the lineage of origin of apoptotic cells may ultimately
dictate the outcome of cross-presentation. This notion may help
reconcile several apparently contradictory ﬁndings. For example,
it explains why apoptotic cells derived from epithelial or resting
T cells that are CD40L− are unable to provide DC maturation
stimuli and are tolerogenic in the absence of sustained infec-
tious/inﬂammatory signals (De Vita et al., 1998; Propato et al.,
2001;Albert, 2004; Kazama et al., 2008). Thus, the balance between
CD40L+ and CD40L− apoptotic cells during cross-presentation
appears to dictate tolerance or induction of CD8 T cell responses
against T-cell-associated epitopes, and to maintain or to stop
the related responses in the course of an inﬂammatory process.
These responses have a critical role in the ampliﬁcation of chronic
inﬂammation via the continuous bystander effects of inﬂam-
matory cytokines produced by T cells speciﬁc for the apoptotic
T-cell-associated antigens (Propato et al., 2001; Rawson et al.,
2007).
For all these reasons, adaptive immune responses clearly show a
deeper level of ambiguity: (a) an effective T cell response depends
on an adequate level of tissue inﬂammation, which in turn also
induce tissue injury; (b) effector lymphocyte responses are both
protective and harmful at the same time.
However, the ambiguity appears to be not only advantageous
but also necessary. Indeed, the control of a given infectious agent
(protection) is dependent on the immunopathological process at
the level of the site of infection (damage), which generally results
in an acute disease undergoing recovery when the anti-pathogen
responses are prompt and efﬁcient. In this situation, the con-
traction of both protective effector responses and the associated
immunopathological process (e.g., delayed hypersensitivity Th1
or likely Th17 cell responses, including the autoreactive, “allergic-
like” hypersensitivity Th2 cell responses) occurs in relation to
the clearance of intra or extracellular pathogens (Figure 2). In
addition, even the autoreactive and the apparently useless T or
B responses that can arise together with the protective responses
via the mechanisms described previously are beneﬁcial in sup-
porting the immunopathology required for the recovery: also,
these responses generally disappear in relation with the pathogen
Frontiers in Immunology | Inﬂammation February 2012 | Volume 3 | Article 18 | 6
Barnaba et al. Ambiguity in immunology
FIGURE 3 |The balance between CD40L+ and CD40L− apoptotic cells
during cross-presentation dictates induction or tolerance ofT
cell responses. (A) Apoptotic T cells expressing CD40L can directly provide
to DCs both (apoptotic cell-derived) self antigens and the necessary
maturation stimuli for T cell priming. (B) Under conditions in which the
CD40L+ apoptotic T cells are overwhelmed by the CD40L− apoptotic cells
(i.e., under normal conditions or when an inﬂammatory process is
terminated), the latter will be unable to provide the appropriate signals to
DCs, which will deliver tolerance signals to autoreactive T cells, even though
they carry apoptotic cell-derived peptides.
clearance (Di Rosa and Barnaba, 1998; Murali-Krishna et al.,
1998).
Paradoxically, the possibility of recovering from a given
infection is dependent on the high level of immunopathology
(acute disease; Figure 2). Conversely, weak responses are gener-
ally associated with low-grade, long-lasting inﬂammation that,
although causes minimal tissue injury, will be unable to clear the
pathogen, which in turn will persist and, together with the per-
sistent weak immune responses, will lead to irreversible chronic
diseases.
THE CONTROL OF THE IMMUNE RESPONSE
The ambiguity of the immune response can be found at fur-
ther other levels. One important aspect is the downregulation of
the immune response itself. The mechanisms evolved to control
the ongoing effector response may be achieved by multiple, non-
mutually exclusive mechanisms of peripheral tolerance, including
T cell anergy, apoptosis, or exhaustion (Lanzavecchia and Sallusto,
2001; Walker and Abbas, 2002; Steinman et al., 2003; Barron et al.,
2008).
The extinction of effector responses often involves the secre-
tion of immunosuppressive cytokines by T helper themselves, such
as IL-10 and IL-22. These two molecules, belonging to the same
family, operate to rescue immune and tissue homeostasis, respec-
tively (Sanjabi et al., 2009). Indeed, IL-10R is mainly expressed by
immune cells, mediating the inhibition of proinﬂammatory sig-
nals; conversely, IL-22R is present predominantly on the surface
of epithelial and tissue cells. This cytokine has revealed some
functional ambiguity: on the onehand,during acute inﬂammatory
reactions in gut and liver, IL-22 protects the tissue from immune-
mediated injury, facilitates regeneration, promotes secretion of
antimicrobial substances and maintains barrier integrity against
bacterial translocation (Zenewicz et al., 2008; Zheng et al., 2008);
on the other hand, IL-22 becomes pathogenic in skin diseases, fos-
tering keratinocyte hyperplasia, and local inﬂammation (Duhen
et al., 2009; Eyerich et al., 2009). Thus, the activities of IL-22 may
result beneﬁcial or detrimental to the host depending on tissue
type, cytokine milieu, and target cells.
A special emphasis has been recently placedon thePD-1,a death
receptor over-expressed by chronically stimulated lymphocytes
that induces peripheral TorB cell toleranceupon the simultaneous
interaction of TCR or BCR with antigens and of PD-1 with its own
ligands: PD-L1, which is virtually expressed on all somatic cells
(particularly from inﬂamed tissues; Keir et al., 2006; Sharpe et al.,
2007), and PD-L2, which is mainly expressed by DCs. However,
thismechanismbecomes detrimentalwhen thePD-1/PD-L1 inter-
action takes place in tissues infected with persistent pathogens, via
its capacity to induce exhaustion of antimicrobial T cell responses
(Probst et al., 2005;Barber et al., 2006;Day et al., 2006; Sharpe et al.,
2007). Through this mechanism, effector lymphocytes express the
death receptor PD-1 and are blocked in their functional abilities
when interact with cells expressing PD-L1, the counter-receptor,
which is the case with epithelial cells when chronically infected
by a virus or during an inﬂammatory process (Probst et al., 2005;
www.frontiersin.org February 2012 | Volume 3 | Article 18 | 7
Barnaba et al. Ambiguity in immunology
Barber et al., 2006; Day et al., 2006; Keir et al., 2006; Sharpe et al.,
2007).
The extrinsic mechanisms of peripheral tolerance are put into
action mainly by CD4+CD25+Foxp3+ Treg cells (Shevach, 2002;
Bluestone and Abbas, 2003; von Boehmer, 2005). These cells
develop either in the thymus (natural) or in the periphery from
conventional CD4+ T cells (induced), and express the transcrip-
tion factor Foxp3 (Shevach, 2002; Bluestone and Abbas, 2003;
Fontenot et al., 2003; Hori et al., 2003; Sakaguchi, 2004; von
Boehmer, 2005; Ziegler, 2006). A lack of Foxp3 expression results
in the complete absence of Treg cells, which leads to the develop-
ment of severe autoimmunity, as observed in immuno dysregula-
tion polyendocrinopathy enteropathy X-linked (IPEX) syndrome.
Treg cells induce suppression via several mechanisms, involving
membrane molecules, such as CTLA-4 or adenosine receptors,
suppressive cytokine production, such as TGF-β or IL-10, domi-
nant absorption of IL-2 by high CD25 expression (Shevach et al.,
2001; Shevach, 2002; von Boehmer, 2005; Belkaid, 2007; Deaglio
et al., 2007; Pandiyan et al., 2007; Vignali et al., 2008). Because
of the expression of the Il2 gene-inhibitory Foxp3 transcription
factor, Treg cells do not produce IL-2 and are unable to respond
to antigens (anergy; Schubert et al., 2001; Coffer and Burgering,
2004; Fontenot et al., 2005). However, they promptly proliferate
in response to relevant antigens in the presence of paracrine IL-
2, which is mainly produced by effector T lymphocytes but is
dominantly absorbed by Treg cells via the high expression of IL-
2 receptors (CD25 high; de la Rosa et al., 2004; Barthlott et al.,
2005; Kretschmer et al., 2005; Scheffold et al., 2005; Setoguchi
et al., 2005). The main physiological functions of Treg cells are as
follows: (a) to participate in the establishment of peripheral tol-
erance by inhibiting autoreactive lymphocytes that escaped either
thymus or bone marrow checkpoints (central tolerance), (b) to
suppress ongoing protective immune responses once they are no
longer necessary or become harmful after the elimination of the
pathogen, and (c) to limit excessive immunopathology during
chronic inﬂammatory diseases (Shevach, 2002; Fontenot et al.,
2003, 2005; Hori et al., 2003; Sakaguchi, 2004; Kretschmer et al.,
2005; Setoguchi et al., 2005; von Boehmer, 2005; Ziegler, 2006;
Belkaid, 2007). The immune system, by using highly specialized
molecular mechanisms, on the one hand attacks the invading
agents, on the other hand it suppresses the same responses. Again,
this ambiguous aspect results in an advantage for the host, because
it is necessary to defend, but also to limit potentially harmful
proinﬂammatory responses.
In the model of hepatitis C virus (HCV) infection,
CD4+CD25+Foxp3+ Treg cells have been proposed to participate
in the establishment of aﬁne equilibriumbetween immunopathol-
ogy and immune protection, ultimately resulting in the long-
lasting survival of the host during chronic infections (Shevach,
2002; Accapezzato et al., 2004; von Boehmer, 2005; Belkaid, 2007;
Ward et al., 2007; Ebinuma et al., 2008; Heeg et al., 2009; Figure 2).
This would be dependent on a compromise between a status of
chronic low-level hepatic inﬂammation and the generation of
antiviral responses that, although unable to clear HCV, are enough
to limit excessive viral spread. It is unclear how Treg cells con-
trol unwarranted inﬂammation without completely suppressing
the protective immune responses. High CD25 expression by Treg
cells drives a positive feedback loop, as the dominant IL-2 capture
increases STAT-5 phosphorylation (pSTAT-5) that in turn drives
Treg cell proliferation and function. We recently showed that PD-1
is over-expressed on Foxp3+ Treg cells and limits Treg cell prolifer-
ation and function during chronic HCV infection. The expression
of PD-1, upon the contact with its own ligands, inhibits pSTAT-5
via the activation of Src homology 2-containing tyrosine phos-
phatases (Franceschini et al., 2009; Figure 4). As a consequence,
responder T cells can escape from excessive expansion of Treg cells
and render them available for responding to possible novel waves
of infection. This negative feedback loop assumes a different sig-
niﬁcance during chronic infections, such as HCV. The incapacity
to clear HCV by the immune system (due to the various mech-
anisms emphasized above) maintains a vicious spiral, whereby
responder T cells are chronically stimulated to produce IL-2 that
will be dominantly adsorbed by CD25hi Treg cells that in turn will
continuously suppress the effector responses. The PD-1 upreg-
ulation limits the excessive expansion of Treg cells by controlling
pSTAT-5 and ﬁne-tunes the Treg function in order to minimize the
immunopathology without completely switch off those intended
to limit excessive viral spread (Figure 4). This may represent a
critical contra-suppression mechanism that has evolved to con-
trol that Treg cells have a limited suppression. Homeostatic bal-
ance participates in establishing a status of chronic low-level liver
inﬂammation that is in turn instrumental to ensure a long-lasting
survival of the host.
A further level of Treg contra-suppression may be achieved
with Treg trans-differentiation into alternative fates. Indeed, many
recent observations point to an inherent plasticity of Treg cells, par-
ticularly prone to acquire proinﬂammatory functions under ade-
quate microenvironmental cues (Zhou et al., 2009a). For instance,
an unexpected discovery is that human Treg cells have consider-
able plasticity that allows them to produce the proinﬂammatory
cytokine IL-17 under certain conditions particularly related to
autoimmunity (Cvetanovich and Haﬂer, 2010). The Treg plas-
ticity has been related to a CpG-rich intronic enhancer region
known as the Treg-speciﬁc demethylated region (TSDR), present
at the level of four conserved, non-coding regions in the human
Foxp3 locus, and containing the most strikingly Treg-speciﬁc pat-
tern of CpG methylation (Huehn et al., 2009; Lal and Bromberg,
2009). The methylated state of TSDR in activated conventional T
cells and TGF-β-induced Treg cells allows these cells to transiently
express Foxp3. In contrast, the demethylated state of the TSDR
in human Treg cells allows them to be the only cells that gener-
ally exhibit long-term stability of Foxp3 expression. The Foxp3
instability may account for the capacity of conventional T cells
and TGF-β-induced Treg cells expressing Foxp3 to convert into
Th17 cells, particularly when they are strongly activated in the
presence of proinﬂammatory cytokines during different forms of
autoimmune diseases (Dominguez-Villar et al., 2011). The par-
ticipation of TGF-β in the differentiation of Th17 cells places
the Th17 lineage in close relationship with Treg cells, as TGF-
β also induces differentiation of naive T cells into Foxp3+ Treg
cells (Korn et al., 2009). Controversy still exists about the stabil-
ity of Foxp3 expression along Treg reprogramming (Zhou et al.,
2009b; Rubtsov et al., 2010). In any case, Treg cells have been
recognized as the preferential precursors for follicular helper T
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FIGURE 4 | Chronic low-level inflammation as an advantage for the
long-term human survival. Several mechanisms induced by both
persistent pathogens (e.g., escape by pathogen mutations,
pathogen-related immune subversion) and the host [e.g., PD-1-dependent T
cell exhaustion, Regulatory T (Treg) cells] contribute to the maintenance of
chronic inﬂammatory diseases, by down-modulating DC functions, T and B
cell priming, generation of memory cells, and ultimately differentiation of
terminal effector cells. Treg cells can be represented by the following: (a)
CD4+CD25+Foxp3+ Treg cells, which suppress via cell–cell contact, IL-2
capture to effector cells, TGF-β production, etc.; (b) Treg cells producing
immunosuppressive cytokines (e.g., IL-10, TGF-β). PD-1 is upregulated on
both responder andTreg cells and upon contact with PD-L1/2 limits both T
effector memory (TEM) cell responses and excessive Treg cell function,
respectively. The resulting contra-regulation of Treg cells will have an
important role to limit excessive suppression of immune responses allowing
the control of the viral spread, at the cost of the maintenance of the chronic
low-level liver immunopathology. This mechanism establishes a long-lasting
survival of the host.
cells in gut Peyer’s patches (Tsuji et al., 2009) and for CD40L-
expressing helper T cells in the establishment of antitumor immu-
nity (Sharma et al., 2010). Hence, Treg cells may rapidly turn from
immune-suppressive into immune-protective cells in an “innate-
like” fashion (Zhou et al., 2009a). Accordingly, Treg ablation
impaired, rather than promoting, early antiviral local responses
in a mouse model of infection (Lund et al., 2008). The extra-
cellular signals driving Treg plasticity are mostly unknown and
may comprise not only proinﬂammatory cytokines but also cos-
timulatory receptors. OX40 is a receptor belonging to the TNFR
superfamily that is constitutively expressed by Treg cells, support-
ing their homeostasis (Piconese et al., 2010) and regulating Treg
contra-suppression (Piconese et al., 2008). However, it is becom-
ing increasingly clear that the outcome of OX40 signal is somehow
modulated by the cytokine milieu and that, in turn, OX40 may
affect Treg responses to cytokines. Indeed,OX40 enhances Treg sus-
ceptibility to IL-2 (Piconese et al., 2010), and different outcomes
of OX40 stimulation depend on the cytokine context (Ruby et al.,
2009). Therefore, we may envisage a role for OX40, and possibly
for other costimulatory molecules showing comparable behaviors,
in ﬁne-tuning Treg ambiguity in response to microenvironmental
soluble signals.
IMMUNITY/IMMUNOPATHOLOGY BALANCE, AS A MODEL
OF AMBIGUITY
As suggested above, we can assume that the contradictory aspect
of the immune response is the result of the evolution of biologi-
cal systems. This evolution proceeds through the selection of the
most advantageous processes to ensure the survival of the species.
Conversely, these selected processes may have a high cost for the
single individual in terms of morbidity and/or mortality. There-
fore, a ﬁne line exists between immunity and immunopathology,
because, as previously discussed, it is not possible to obtain an
effective immune response without the onset of immunopathol-
ogy. A problem arises when the immunopathologic reactions
become persistent or chronic, producing irreversible damage to
tissues and organs. Indeed, chronic inﬂammation may be inter-
preted as an adaptive response to challenges producing irreversible
modiﬁcations of tissue homeostasis, often at the expenses of tissue
functions (Medzhitov, 2010). A sustained inﬂammatory response
can also be responsible for the development of tumors. In the next
section, we will discuss the main mechanisms of chronic inﬂam-
mation and the ambiguity of this process, which not only helps to
control persistent infections but also may induce severe disease of
the host (i.e., autoimmunity, tumors).
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CHRONIC INFLAMMATION AS AN ADVANTAGE FOR SPECIES SURVIVAL
The induction of a state of chronic inﬂammation secondary to
infections occurs for those pathogens that are able to evade the
immune response and establish a status of persistence. Typical
microorganisms capable of evading the immune system and of
establishing chronic diseases in humans include HIV, hepatitis B
virus (HBV), HCV, Mycobacterium tuberculosis, and Leishmania
(Zinkernagel, 1996; Zinkernagel et al., 1999; Tortorella et al., 2000;
Phillips, 2002; Klenerman and Hill, 2005).
The relationship between the host and the latent viruses, partic-
ularly the herpesviruses (i.e., herpes simplex virus, Epstein–Barr
virus, cytomegalovirus), is completely different. These viruses
generally establish latency in speciﬁc cell types or tissues, are con-
tinuously controlled by the immune system, and, in contrast to the
persistent pathogens previously mentioned, remain lethargic with
regard to their replication capacity (Nikolich-Zugich, 2008). Only
occasionally, these viruses are reactivated and stimulate memory T
cells,which are generally capable of returning the virus to a state of
latency. In a very tiny number of healthy carriers, these viruses can
degenerate in severe forms of tumors. However, the intermittent
(but not continuous, as in the case of persistent pathogens) T cell
stimulation does not result in the impairment or exhaustion of
antigen-speciﬁc T cells and the development of chronic diseases.
Latent viruses seem to play a critical role in expanding memory T
cell populations and in maintaining constant their frequencies in
old age. Therefore, we will not discuss latent viruses further in this
review, which aims to deﬁne the role of chronic inﬂammation in
long-term host survival during persistent infections.
Through the different (non-mutually exclusive) mechanisms
illustrated above, the host could survive for a long time in parallel
with both the “partially controlled” persistent agent and a low-
grade inﬂammation. Therefore, chronic inﬂammatory processes
are paradoxically useful, supporting the concept that the ambigu-
ity is advantageous for the evolutionary process. If the immune
responses were invariantly strong and aggressive during a per-
sistent infection, they would be unable to eliminate the persis-
tent pathogen, because of the acquired capacity by the persistent
pathogen to escape or to subvert them. In such a situation, exu-
berant (but non-protective) responses would produce irreversible
tissue damage in the host, leading to catastrophic epidemic infec-
tions. Considering this point of view, chronic (low-level) inﬂam-
matory diseases seem to represent a sort of safeguard for the
human survival!
We can assume that chronic inﬂammation may be deﬁned
as the “Yin and Yang” of the immune system, because, via the
sophisticated mechanisms mentioned previously, it guarantees the
long-term survival of human hosts despite the pathogen persis-
tence. However, the imbalance of the homeostatic mechanisms
maintaining chronic inﬂammation may degenerate into severe
“side effects” (i.e., the development of either autoimmune diseases
or tumors) in some individuals (Figure 5).
AUTOIMMUNITY AND CANCER
From an evolutionary point of view, the onset of autoimmune
diseases or of some tumors might be the price to pay following
the establishment of chronic inﬂammation. It has been suggested
that the intensity and nature of the inﬂammation might explain
FIGURE 5 | Chronic inflammatory diseases as the “Yin andYang” of the
immune system. Under conditions in which the immune system has been
bypassed by persistent pathogens, chronic low-level inﬂammation
guarantees long-term survival of the majority of infected individuals in spite
of pathogen persistence. The imbalance of the homeostatic mechanisms
maintaining chronic inﬂammation may degenerate into severe “side
effects” (such as autoimmune disorders or tumors) in some individuals.
However, these side effects are considered irrelevant in terms of the
survival of the species.
the apparent contradiction between the inducing and inhibiting
effects on tumor survival. Indeed, vigorous acute inﬂammatory
processes can favor an immune effector responsepotentially able to
induce tumor regression (Mantovani et al., 2008a,b). Conversely, a
status of pre-existing chronic inﬂammation can participate to the
development of cancer, by the production of growth and angio-
genic factors eventually promoting cancer-cell survival, implanta-
tion, and growth. In addition, chronic inﬂammation can affect the
immune-surveillance directly via its own intrinsic mechanisms
(i.e., expansion of Treg cells, T cell exhaustion, etc.), and indi-
rectly by the incapacity to limit the immunosuppressive effects
by tumors. In these conditions, the suppression of the immune
response, that is certainly useful to terminate the effector responses
or to limit excessive immunopathology, can result detrimental. In
fact, the chronic activity of Treg cells is believed to play a cru-
cial role in suppressing the immune-surveillance against tumors
by CD8+, Th1, and probably Th17 cells (Curiel et al., 2004; Zou,
2006; Colombo and Piconese, 2007; Curiel, 2007; Nair et al., 2007;
Zhou and Levitsky, 2007; Piconese et al., 2008).
The production of soluble factors (i.e., proinﬂammatory or cell
growth cytokines) that favor cell proliferation, generally needed
to the immune system to defend the host efﬁcaciously, can facil-
itate the mitotic cycle also of non-lymphoid cells. In the long
run, this prolonged stimulation, which is characteristic of chronic
inﬂammatory processes, can induce tissue damage, as in the case
of liver cirrhosis by both HBV and HCV, where the phenomena of
necrosis, cell renewal, and even neoplastic transformation might
simultaneously occur (Tan et al., 2008). The sustained recogni-
tion of antigens that cannot be eliminated by the immune system
can induce errors in VDJ rearrangement by B cells or cause chro-
mosomal translocations. These conditions can generate the onset
of lymphomas. A typical case is the mucosa-associated lymphoid
tissue (MALT) lymphoma associated with the presence of sev-
eral infectious agents including Helicobacter pylori,Campylobacter
jejuni,Borrelia burgdorferi,Chlamydia psittaci, and HCV, inducing
gastric lymphomas, immunoproliferative small intestinal disease,
cutaneous lymphoma, ocular lymphoma, and spleen lymphoma,
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FIGURE 6 | Chronic immune activation as a result of cross-presentation
of apoptoticT cells. During severe inﬂammatory processes, chronic immune
activation may be in part maintained by a vicious spiral, which may be initiated
by activated lymphocytes (e.g., speciﬁc for persistent microbial antigens or
self antigens) undergoing apoptosis upon they performed their effector
functions. These apoptotic cells are cross-presented by DCs, which
cross-prime a huge repertoire of autoreactiveT cells speciﬁc for a multitude of
apoptotic cell-associated epitopes. Apoptotic antigen-speciﬁc T cells
participate to the maintenance of chronic immune activation via their effector
performances, then they will undergo apoptosis, and the resulting apoptotic
cells will be cross-presented by DCs that will cross-prime new waves of
apoptotic antigen-speciﬁc T cells, and so on.
respectively, following the chronic stimulation of local B cells
(Suarez et al., 2006; Sagaert et al., 2007). In addition, the chronic
stimulation of B lymphocytes by HCV infection can induce the
monoclonal expansion of anti-IgG antibodies, which are respon-
sible for the formation of cryoglobulins or even the establishment
of follicular B cell lymphomas (Landau et al., 2007).
Another complex issue deserving discussion is how autoreac-
tive T lymphocytes become pathogenetic and develop chronic
autoimmune diseases. Under conditions in which the stimula-
tory capacities gain the upper hand over the tolerogenic capacities
of DCs (i.e., during inﬂammatory or infectious processes), they
phagocytose both microbial and self antigens and migrate with
high efﬁciency into the draining lymph nodes, where they efﬁ-
ciently prime both pathogen-speciﬁc and autoreactive T cells
(Lang et al., 2005; Marshak-Rothstein, 2006). Generally (as pre-
viously discussed in the B Cell Responses and T Cell Responses),
these responses are switched off when the pathogen has been
cleared, including the autoreactive responses that have participated
in the ampliﬁcationof the protective responses.Under certain con-
ditions, several genetic and environmental factors (many of which
are still unknown) can, however, allow the expansion of autoreac-
tive clones, which escape the mechanisms of peripheral tolerance,
and can induce autoimmune diseases.
In this context, it is of interest our recent observation indicating
that the phenomenon of chronic immune activation, commonly
observed during different viral or autoimmune diseases (Propato
et al., 2001; Chernysheva et al., 2002; Bangs et al., 2006; Gross-
man et al., 2006), is in part caused by a vicious cycle, which
is maintained by a continuous cross-presentation of apoptotic
lymphoid cells that are derived from chronically activated lym-
phocytes (Figure 6; Rawson et al., 2007). The phagocytosis of these
apoptotic cells by DCs leads to the generation of a huge number
of apoptotic cell-derived self-epitopes. In a chronic inﬂamma-
tory context and in virtue of the activatory signals provided by
apoptotic T cells expressing CD40L, this activity also leads to the
cross-priming of a large repertoire of apoptotic epitope-speciﬁc T
cells, which in turn expand the inﬂammation and undergo apop-
tosis after they have performed their effector functions, and so on
(Propato et al., 2001; Rawson et al., 2007). Thus, chronic immune
activation can establish a milieu favoring the emergence and the
maintenance of autoimmune responses, and ultimately contribute
to the irreversible impairment of the immune system, such as in
the case of HIV infection or in the ﬁnal stages of several sys-
temic autoimmune diseases (Propato et al., 2001; Rawson et al.,
2007).
Finally, functional defects of Treg cells seem to play a key role in
the induction of autoimmune processes. Defects of these cells have
been clearly documented in several autoimmune diseases (e.g.,
rheumatoid arthritis, type I diabetes, multiple sclerosis; Chate-
noud et al., 2001; Shevach et al., 2001; Bluestone and Abbas, 2003;
von Herrath and Harrison, 2003; Ehrenstein et al., 2004; Hsieh
et al., 2004; Lerman et al., 2004; Tang et al., 2004; Viglietta et al.,
2004; Lindley et al., 2005; Sakaguchi, 2005) as well as in allergic
diseases (Medoff et al., 2008). Similar mechanisms play a crucial
role in the uncontrolled generation of autoantibodies recognizing
apoptotic cell-associated self-epitopes, as in the case of several sys-
temic autoimmune diseases (i.e., systemic lupus erythematosus,
progressive systemic sclerosis, Sjogren’s diseases; Chatenoud et al.,
2001; Shevach et al., 2001; Bluestone and Abbas, 2003; von Her-
rath and Harrison, 2003; Ehrenstein et al., 2004; Hsieh et al., 2004;
Lerman et al., 2004; Tang et al., 2004; Viglietta et al., 2004; Lindley
et al., 2005; Sakaguchi, 2005).
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CONCLUSION
Based on the deﬁnition of ambiguity as “a symptom of the cri-
sis of the subject, a productive function against and beyond the
metaphysic (creativity),” we can consider this concept as a hall-
mark of biological systems. When the deﬁnition of ambiguity
is applied to the immune system, the “crisis” should derive by
its capacity to recognize everything and thus to risk to offend
and not only to defend the host. Therefore, the “creativity” of
the immune system consists of its capacity to express simul-
taneously different strategies that are only apparently oppo-
site but eventually result in an evolutionary advantage. On the
one hand, the immune response contributes to the species sur-
vival; on the other hand, it can lead to the sacriﬁce of sin-
gle individuals. During the evolutionary process, the selective
pressure led to the generation of multiple ambiguous mecha-
nisms to better counteract the aggression of infectious agents.
Although this is obtained at the cost of severe side effects (tumor
development, autoimmune diseases) in several individuals, these
side effects are considered irrelevant in terms of the survival of the
species.
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